ISO 10993-23 In vitro irritation testing for medical devices: Substantiating applicability to mild irritants and non-extractables

被引:0
|
作者
Pellevoisin, Christian [1 ]
Coleman, Kelly P. [2 ]
Hoffmann, Sebastian [3 ]
机构
[1] EpiSkin, 4 Rue Alexander Fleming, F-69366 Lyon 7, France
[2] Medtronic Plc, Minneapolis, MN USA
[3] Seh Consulting Serv, Paderborn, Germany
关键词
Skin irritation; In vitro; Medical device safety; Reconstructed human epidermis; Mild irritants; Applicability domain;
D O I
暂无
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Irritation testing is an integral part of the biocompatibility assessment of medical devices and has historically been conducted on animals, either by direct contact or with polar and non-polar solvent extracts. In 2018 an ISO-sponsored interlaboratory validation study demonstrated that two reconstituted human epidermis (RhE) based assays, which were adapted from validated methods used for industrial chemicals, produced results essentially equivalent to those obtained with in vivo tests. This led to the publication of the ISO 10993-23:2021 standard on irritation testing, which states that RhE-based assays are now the preferred method. The 2018 validation study evaluated strong irritants, so we tested nine mild irritants (GHS Category 3), neat and spiked at different concentrations into medical device extracts, per ISO 10993-23:2021. The results substantiated the applicability of RhE-based assays for evaluating mild irritants in medical device extracts. Moreover, the 2018 validation study tested solid extractable medical device materials but did not consider non-extractable medical device materials (e.g., creams, gels, or sprays). By testing nine marketed non-extractable materials, either neat or spiked with irritants, we also confirmed that RhE-based assays are readily applicable to such medical device materials.
引用
收藏
页数:7
相关论文
共 3 条